FDA Approves New Hepatitis B Drug Hibsago

The United States Food and Drug Administration approved a new chronic hepatitis B treatment named Hibsago on October 20, 2026, ChimpReports reported. The medication was developed by the pharmaceutical company GSK. ChimpReports noted that the drug, also known as bepirovirsen, represents the first antisense oligonucleotide therapy authorized by the FDA for chronic hepatitis B treatment. [1]

According to reports by ChimpReports, Pharmaceutical Executive, Contagion Live, and ABP Live English, the approval introduces a novel therapeutic option for individuals managing chronic hepatitis B infections. The therapy works by targeting the virus in a way that may enable select patients to stop taking regular antiviral drugs while maintaining control over the infection. [1][2][3][4]